Business

SpotLite360 (CSE-LITE) made Huge gains since trading began, and could continue trending uphill.

SpotLite360 (CSE-LITE) made Huge gains since trading began, and could continue trending uphill.

Put LITE on your Watchlist NOW

3 Critical Events Have Made SpotLite360 the Darling of the Canadian Securities Exchange!

Here are the 3 critical events that could forever change supply chain technology!

  1. The chart is on fire!
  2. In 2023, less than 2 years away, the FDA announced that they are making it mandatory to, “identify and trace certain prescription drugs as they are distributed throughout the U.S.” 2
  3. The FDA has proposed new traceability rules on critical tracking supply chain activities to combat the food fraud costs the industry $40 billion annually and the food-borne pathogens costs of $55.5 billion per year!

Company Name: SpotLite360

Ticker: CSE-LITE

Company Summary: SpotLite360 is a SaaS-based, enterprise software company leveraging IoT technologies, blockchain, & machine learning to deliver supply chain solutions which result in improved tracing, tracking, visibility, efficiency, collaboration & proof of sustainability claims for customers within pharmaceutical, healthcare & agriculture.

What do they do?

In lay terms, they develop software that improves tracing, tracking, visibility, efficiency, collaboration & proof of sustainability claims for customers within pharmaceutical, healthcare & agriculture. SpotLite360’s software allows companies to have a real-time view of inventory all over the world with a click of a mouse! Imagine if this software or software like it, was mandatory? The pandemic would have been way different, we would have had toilet paper, LOL!

#1. The trading for LITE is in an aggressive bullish trend with possibly no end in sight, producing 100% gains in a month!

 

SpotLite360-Chart

As you can see in this chart found above, this stock is absolutely trending extremely bullish. All indicators are positive and likely to continue in this upward trend line. In regards to the technicals, it is a STRONG BUY! 7

SpotLite360-Technicals

#2. In 2023, less than 2 years away, the FDA announced that they are making it mandatory to, “identify and trace certain prescription drugs as they are distributed throughout the U.S.” 2

Take a look at this quote by an industry giant in the supply chain management:

Mike Crum, a professor and chair of supply chain management in Iowa State University’s Ivy College of Business was asked, Why is the government an important part of the supply chain?

“The government, through investments, financial incentives, regulations, and policies, greatly [affects] supply chain performance.” 3

It is clear, the writing is on the wall, whether you like it or not big brother is coming with mandates! The libertarians will be sounding the alarm that the police state is being ushered in, the Dems will be cheering the victory and the consumer will be tickled pink when essential goods will be available during the next crisis. As a trader, you have a rare opportunity to profit from big brother’s mandates.

In Big Pharma’s case it’s not if the government will mandate better supply chain technology, it’s when because we have the date!

In 2023, less than 2 years away, the FDA announced that they are making it mandatory to, “identify and trace certain prescription drugs as they are distributed throughout the U.S.”

Take a look at this excerpt from the FDA website!

The Drug Quality and Security Act (DQSA), was enacted by Congress on November 27, 2013. Title II of DQSA, the Drug Supply Chain Security Act (DSCSA), outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States. 2

Big brother is mandating that pharma companies must follow federal guidelines in regards to certain drugs, this is the reason why:

  • More than $1 billion in drug thefts annually
  • $236 billion in counterfeit drugs causing harm to the populace
  • 25% of vaccines damaged in transit, another result of Covid
  • 20% temperature sensitive drugs perish.

These mandates are looming, they are right around the corner and trillion dollar mega-companies will be scrambling to be compliant and SpotLite360 will be knocking on their door with possibly the best solution in the market with decades of experience!

Don’t believe me, this is an excerpt taken from the FDA website.

This will enhance FDA’s ability to help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. The system will also improve detection and removal of potentially dangerous drugs from the drug supply chain to protect U.S. consumers.2

SpotLite360-DSCSA

The above screen shot was taken from the FDA website.

If the big Pharma mandate by the federal government gets you excited, there are two mandates that will greatly impact SpotLite360! Take a look at this!

#3. The FDA has proposed new traceability rules on critical tracking supply chain activities to combat the food fraud costs the industry $40 billion annually and the food-borne pathogens costs of $55.5 billion per year!

Take a look at the following excerpt from the FDA’s website,

“The Drug Quality and Security Act (DQSA), was enacted by Congress on November 27, 2013. Title II of DQSA, the Drug Supply Chain Security Act (DSCSA), outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States.” 2

On July 13, 2020, the FDA released the Blueprint for the New Era of Smarter Food Safety. The blueprint outlines the FDA’s vision to enhance traceability, improve predictive analytics, respond more rapidly to outbreaks, address new business models, reduce contamination of food, and foster the development of stronger food safety cultures. Although the FSMA 204 rulemaking is limited to only certain foods, the blueprint identifies it as a foundational first step on the path to promoting tech-enabled end-to-end traceability for all foods. The proposed rule, when finalized, would establish a standardized approach to traceability recordkeeping, paving the way for industry to adopt, harmonize, and leverage more digital traceability systems in the future.

From the FDA’s website, “A modern, coordinated approach to traceability that can be used and understood throughout all stages of the food supply chain will go further to reduce foodborne illness, build consumer trust, and avoid overly-broad recalls.” 5

The federal government is pushing for these laws to ensure safety for its constituents and to respond to the majority who are interested in where their food comes from.

56% of shoppers want to know where their food comes from. 6

Our world, whether we like it or not, is headed towards: organic, lactose free, grass fed, grown in the USA, Kobe, farm raised, cruelty free and so on and so on. As the demand for thoses nomenclatures grow, the demand for the proof of those labels increases too.

56% of shoppers want to know where their food comes from. SpotLite360 (CSE-LITE) specializes in supply chain management via a SaaS platform that can meet the demands of those 56% that are demanding certificate of origin.

FDA is establishing these rules to tackle to avoid these problems:

  • Lack of visibility allows opportunities for product tampering and theft
  • 68% of consumers will pay more for products that are produced ethically and responsibly
  • As much as 60% of all food produced is wasted and never makes it to the consumer ($1 trillion)
  • Food-borne pathogens costs consumers $55.5 billion per year
  • Food fraud costs the industry $40 billion annually

SpotLite360 is catering to three verticals: agriculture, big pharma and healthcare. Of the three, two have or will have mandates to utilize the technology that SpotLite360 has developed. SpotLite360 will be funding its efforts to penetrate and control as much of the market share via a public offering. We are incredibly excited to share this information with you and highly encourage you to place SpotLite360 on your watchlist TODAY.

As A Quick Recap, the THREE Top Reasons to Put (CSE-LITE) on Your Watchlist Today!

  1. The chart is on fire!
  2. FDA announced that they are making it mandatory to identify and trace certain prescription drugs as they are distributed throughout the U.S., that could be worth TRILLION$!
  3. The FDA has proposed new traceability rules in regards to agriculture, people care about the efficacy of organic food!

1. https://uploads-ssl.webflow.com/603ffdbf0489872a5df6049e/605b6ae644f8e8b2989bff3c_spotliteeefinal.pdf

2. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-takes-steps-enhance-drug-supply-chain-security-setting-new-recommended-data-standards

3. https://www.futurity.org/supply-chain-us-government-2535692/

4. https://mitsloan.mit.edu/ideas-made-to-matter/post-pandemic-supply-chains-retool-a-new-abnormal

5. https://www.fda.gov/food/new-era-smarter-food-safety/tracking-and-tracing-food

6. https://www.spotlite360.com/investors

7. https://www.tradingview.com/symbols/CSE-LITE/

Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, SpotLite360. Small Cap Exclusive has been hired by SpotLite360 for a period beginning on July 10, 2021 for 3 months to publicly disseminate information about SpotLite360 via website and email. We have been compensated $50,000 USD. We will update any changes to our compensation.

Read full disclaimer here.

read more
SpotLite360 Made Huge Gains Since Trading Began in CANADA, NOW is the Time for US Traders

SpotLite360 Made Huge Gains Since Trading Began in CANADA, NOW is the Time for US Traders

THREE Critical Events Have Made SpotLite360 the Darling of the Canadian Securities Exchange, Now They are Ready to Take on Wall Street!

Here are the 3 critical events that could forever change supply chain technology!

  1. The chart is on fire!
  2. In 2023, less than 2 years away, the FDA announced that they are making it mandatory to, “identify and trace certain prescription drugs as they are distributed throughout the U.S.” 2
  3. The FDA has proposed new traceability rules on critical tracking supply chain activities to combat the food fraud costs the industry $40 billion annually and the food-borne pathogens costs of $55.5 billion per year!

Company Name: SpotLite360

Ticker:

Company Summary: SpotLite360 is a SaaS-based, enterprise software company leveraging IoT technologies, blockchain, & machine learning to deliver supply chain solutions which result in improved tracing, tracking, visibility, efficiency, collaboration & proof of sustainability claims for customers within pharmaceutical, healthcare & agriculture.

SpotLite360 is ready to pounce on this archaic market and establish itself as the market leader of this TRILLION dollar a year industry!

SpotLite360 is a technology company that operates in the supply chain vertical. More importantly, they are in the midst of an IPO (initial public offering). Get ready because this company is poised to possibly make a historic run.

 

READ THE LATEST NEWS ON SPOTLITE 360 HERE!

 

What do they do?

In lay terms, they develop software that improves tracing, tracking, visibility, efficiency, collaboration & proof of sustainability claims for customers within pharmaceutical, healthcare & agriculture. SpotLite360’s software allows companies to have a real-time view of inventory all over the world with a click of a mouse! Imagine if this software or software like it, was mandatory? The pandemic would have been way different, we would have had toilet paper, LOL!

The 3 critical events that could forever change supply chain technology!

#1. The chart is on fire!

#2. In 2023, less than 2 years away, the FDA announced that they are making it mandatory to, “identify and trace certain prescription drugs as they are distributed throughout the U.S.” 2

#3. The FDA has proposed new traceability rules on critical tracking supply chain activities to combat the food fraud costs the industry $40 billion annually and the food-borne pathogens costs of $55.5 billion per year!

#1. The chart is in an aggressive bullish trend with no end in sight, producing 100% gains in a month!

SpotLite360-Chart

As you can see in this chart found above, this stock is absolutely trending extremely bullish. All indicators are positive and likely to continue in this upward trend line. In regards to the technicals, it is a STRONG BUY! 7

SpotLite360-Technicals

#2. In 2023, less than 2 years away, the FDA announced that they are making it mandatory to, “identify and trace certain prescription drugs as they are distributed throughout the U.S.” 2

Take a look at this quote by an industry giant in the supply chain management:

Mike Crum, a professor and chair of supply chain management in Iowa State University’s Ivy College of Business was asked, Why is the government an important part of the supply chain?

“The government, through investments, financial incentives, regulations, and policies, greatly [affects] supply chain performance.” 3

It is clear, the writing is on the wall, whether you like it or not big brother is coming with mandates! The libertarians will be sounding the alarm that the police state is being ushered in, the Dems will be cheering the victory and the consumer will be tickled pink when essential goods will be available during the next crisis. As a trader, you have a rare opportunity to profit from big brother’s mandates.

In Big Pharma’s case it’s not if the government will mandate better supply chain technology, it’s when because we have the date!

In 2023, less than 2 years away, the FDA announced that they are making it mandatory to, “identify and trace certain prescription drugs as they are distributed throughout the U.S.”

Take a look at this excerpt from the FDA website!

The Drug Quality and Security Act (DQSA), was enacted by Congress on November 27, 2013. Title II of DQSA, the Drug Supply Chain Security Act (DSCSA), outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States. 2

Big brother is mandating that pharma companies must follow federal guidelines in regards to certain drugs, this is the reason why:

  • More than $1 billion in drug thefts annually
  • $236 billion in counterfeit drugs causing harm to the populace
  • 25% of vaccines damaged in transit, another result of Covid
  • 20% temperature sensitive drugs perish.

These mandates are looming, they are right around the corner and trillion dollar mega-companies will be scrambling to be compliant and SpotLite360 will be knocking on their door with possibly the best solution in the market with decades of experience!

Don’t believe me, this is an excerpt taken from the FDA website.

This will enhance FDA’s ability to help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. The system will also improve detection and removal of potentially dangerous drugs from the drug supply chain to protect U.S. consumers.2

SpotLite360-DSCSA

The above screen shot was taken from the FDA website.

If the big Pharma mandate by the federal government gets you excited, there are two mandates that will greatly impact SpotLite360! Take a look at this!

#3. The FDA has proposed new traceability rules on critical tracking supply chain activities to combat the food fraud costs the industry $40 billion annually and the food-borne pathogens costs of $55.5 billion per year!

Take a look at the following excerpt from the FDA’s website,

“The Drug Quality and Security Act (DQSA), was enacted by Congress on November 27, 2013. Title II of DQSA, the Drug Supply Chain Security Act (DSCSA), outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States.” 2

On July 13, 2020, the FDA released the Blueprint for the New Era of Smarter Food Safety. The blueprint outlines the FDA’s vision to enhance traceability, improve predictive analytics, respond more rapidly to outbreaks, address new business models, reduce contamination of food, and foster the development of stronger food safety cultures. Although the FSMA 204 rulemaking is limited to only certain foods, the blueprint identifies it as a foundational first step on the path to promoting tech-enabled end-to-end traceability for all foods. The proposed rule, when finalized, would establish a standardized approach to traceability recordkeeping, paving the way for industry to adopt, harmonize, and leverage more digital traceability systems in the future.

From the FDA’s website, “A modern, coordinated approach to traceability that can be used and understood throughout all stages of the food supply chain will go further to reduce foodborne illness, build consumer trust, and avoid overly-broad recalls.” 5

The federal government is pushing for these laws to ensure safety for its constituents and to respond to the majority who are interested in where their food comes from.

56% of shoppers want to know where their food comes from. 6

Our world, whether we like it or not, is headed towards: organic, lactose free, grass fed, grown in the USA, Kobe, farm raised, cruelty free and so on and so on. As the demand for thoses nomenclatures grow, the demand for the proof of those labels increases too.

56% of shoppers want to know where their food comes from. SpotLite360 specializes in supply chain management via a SaaS platform that can meet the demands of those 56% that are demanding certificate of origin.

FDA is establishing these rules to tackle to avoid these problems:

  • Lack of visibility allows opportunities for product tampering and theft
  • 68% of consumers will pay more for products that are produced ethically and responsibly
  • As much as 60% of all food produced is wasted and never makes it to the consumer ($1 trillion)
  • Food-borne pathogens costs consumers $55.5 billion per year
  • Food fraud costs the industry $40 billion annually

SpotLite360 is catering to three verticals: agriculture, big pharma and healthcare. Of the three, two have or will have mandates to utilize the technology that SpotLite360 has developed. SpotLite360 will be funding its efforts to penetrate and control as much of the market share via a public offering. We are incredibly excited to share this information with you and highly encourage you to place SpotLite360 on your watchlist TODAY.

As A Quick Recap, the THREE Top Reasons to Put SpotLite360 on Your Watchlist Today!

  1. The chart is on fire!
  2. FDA announced that they are making it mandatory to identify and trace certain prescription drugs as they are distributed throughout the U.S., that could be worth TRILLION$!
  3. The FDA has proposed new traceability rules in regards to agriculture, people care about the efficacy of organic food!

 

1. https://uploads-ssl.webflow.com/603ffdbf0489872a5df6049e/605b6ae644f8e8b2989bff3c_spotliteeefinal.pdf

2. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-takes-steps-enhance-drug-supply-chain-security-setting-new-recommended-data-standards

3. https://www.futurity.org/supply-chain-us-government-2535692/

4. https://mitsloan.mit.edu/ideas-made-to-matter/post-pandemic-supply-chains-retool-a-new-abnormal

5. https://www.fda.gov/food/new-era-smarter-food-safety/tracking-and-tracing-food

6. https://www.spotlite360.com/investors

7. https://www.tradingview.com/symbols/CSE-LITE/

Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, SpotLite360. Small Cap Exclusive has been hired by SpotLite360 for a period beginning on July 10, 2021 for 3 months to publicly disseminate information about SpotLite360 via website and email. We have been compensated $50,000 USD. We will update any changes to our compensation.

Read full disclaimer here.

read more
Torchlight Energy (TRCH) Stock Is About To Hit New Highs: A Breakout?

Torchlight Energy (TRCH) Stock Is About To Hit New Highs: A Breakout?

Investors are often known to look for stocks that have managed to deliver strong gains over a reasonably long period of time and such an approach is understandable considering the short-term volatility in certain stocks.

By that token, it could be a good move for investors to start tracking the Torchlight Energy (NASDAQ:TRCH) stock, which has emerged as one of the major gainers in the past six months and clocked gains of 550% during that period. The stock has been on the move in the premarket trading period this morning and has gone up by as much as 33% at the time of writing.

The latest rally in the stock has been triggered by an announcement from the company about a special dividend after the closure of markets yesterday. The dividends are on Torchlight Energy’s Series A preferred shares which are related to its merger transaction with Metamaterial. The company also revealed that those who hold common shares in Torchlight as of June 24, 2021, will receive one Series A preferred share in the company.

The announcement led to a flurry of activity in the company’s stock and it was no surprise that the Torchlight stock jumped yesterday. It is also important to point out that the company expects its merger deal with Metamaterial to be closed before the end of June.

While the announcement might have been a trigger for the rally in the stock during premarket trading period this morning, it is also important to note that the stock seems to have caught the attention of retail traders on the social media platform Stocktwits.

In other words, the stock might have entered the group of ‘meme stocks’ that might now be the target of retail investors. Over the course of the past 24 hours, the stock had the third-highest number of mentions and was only behind AMC Entertainment and Ocugen, the two other noted ‘meme stocks’.

read more
Hunter Technology (HOILF) Stock Is Moving in the Right Direction: Here is Why

Hunter Technology (HOILF) Stock Is Moving in the Right Direction: Here is Why

When a stock gains momentum over several days, then it might be a good move for investors to start taking a closer look into the stock and the company. The Hunter Technology Corp. (OTCMKTS-HOILF) stock has been gaining considerable momentum in recent days and that might have been related to an updated shared by the company last week.

The company, which is involved in the development of global digital marketplaces focused on the worldwide energy trading industry, provided an update on the progress that it has made with regards to the development of its latest offering OilExchange. Hunter Technology also provided an update on the latest investor deck in relation to this product.

It is a highly innovative product and is meant to act as a platform that is going to help sovereign clients with oil supply chain intelligence solutions. However, that is not all. There are some other highly important features that ought to be pointed out.

The oil value chains can be highly complex but the OilExchange platform is capable of providing large oil producers and governments with the necessary transparency that is so necessary. The oil value chain is highly complex and OilExchange provides solutions starting from the stage of production to trade and storage.

The company announced that it is currently on course to come up with the first version of the product at some point in the third quarter of 2021. However, more importantly, the company revealed that it has engaged with regulatory agencies, governments and a range of selected potential customers in relation to OilExchange.

The interactions have proven that the product could have significant market potential when it is eventually launched. The oil industry is massive and oil trading is the bread and butter of some of the biggest oil companies in the world. Hence, it is a product that could bring a lot of value. Investors could do well to keep an eye on Hunter Technologies from now on.

Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, Hunter Technology Small Cap Exclusive has been hired by Star Finance GMBH, Turmstrasse 28,6312 Stenhausen (ZG), Switzerland for a period beginning on June 1, 2021 to publicly disseminate information about (HOILF) via website, email, as well as outside service providers. We have been compensated $50,000 USD. We will update any changes to our compensation.

Read full disclaimer here.

read more
Humbl (HMBL) Stock Moves Towards $1: Should You Hold Or Sell?

Humbl (HMBL) Stock Moves Towards $1: Should You Hold Or Sell?

At the beginning of the year, the HUMBL Inc HUMBL Inc (OTCMKTS:HMBL) stock was among the most popular penny stocks in the market and clocked massive gains as more and more investors piled on to it in a big way. However, things have not been as great after HUMBL hit its 52-week high.

Since then, the stock has declined by as much as 85% and on Monday, the downward spiral continued as the stock tanked by 20%. There was no news about the company on Monday but it might be worthwhile for investors to take a look at a major development from last Friday.

Key Things To Note

On May 7, the company announced that it signed a binding term sheet with regards to the acquisition of Monster Creative LLC. It was a significant announcement from the company and must have caught the attention of investors as well.

It should be noted that Monster Creative is involved in producing creating advertising for the entertainment industry and has gone on to become one of the better known operators in that space. The company had been founded by two veterans of the advertising industry, Kevin Childress and Doug Brandt.

As per the terms of the agreement between HUMBL and Monster Creative, the latter is going to operate its Hollywood studios as an independent business. However, the company is going to collaborate with HUMBL when it comes to the creation of multimedia NFTs (non fungible tokens). In recent times, NFTs have become extremely popular in the creative industries and hence, it might prove to be a sound move from HUMBL in the long run.

On the other hand, Monster Creative is also going to help HUMBL with regards the creation of ticketing experiences for a range of events starting from those in sports and gaming to music and fashion. Despite the decline recorded by the stock in recent days, it might still be worthwhile to keep an eye on the HUMBL stock.

read more
All Eyes on FACT (OTC-FCTI) – The Only Company Fighting This $6 Billion Fraud Market Just Went Public

All Eyes on FACT (OTC-FCTI) – The Only Company Fighting This $6 Billion Fraud Market Just Went Public

The Devil is in the details and this IPO is a Tech Company that examines a multibillion-dollar industry on the microscopic level! What does this company actually do? F.A.C.T, (OTC-FCTI) is the ONLY PORTABLE SOLUTION ON THE MARKET that uses technology to create a “Digital Fingerprints” from the Physical Artwork for Verification and Condition Reporting. Why is this technology so exciting for investors? The art fraud market is estimated by the FBI to be a $6B industry! FACT has positioned itself, with the above mentioned technology, to possibly be the dominant force in the art fraud prevention vertical, which is again a $6B industry. Who are their competitors? The first two questions ask, what do they do and how big is the market. The final question is, who will they be competing with to possibly gain control of this $6B a year industry? Their competition is “art experts” who verify paintings with the naked eye! This process is archaic and ripe with fraud and FACT has made it their mission to solve this dilemma via cutting-edge technology.

6 Reasons why F.A.C.T,(OTC-FCTI) Forensic Art Certification Technology is the IPO to watch and that is a FACT!

1. Numbers don’t lie, and the potential profit is possibly explosive!

I literally did about 20 minutes of research and my jaw hit the floor! It is rare to find a market that is worth so much internationally so antiquated in technology! Furthermore, to find the same industry boasting $6B in annual sales is when the hairs on the back of my neck stood up at attention like a WW2 soldier. Take a look at this quote from Statista.com, “This increase is also shown in the volume of global art sales which reached approximately 40 million transactions in 2018” LINK I rubbed my eyes and thought, 40 million transactions?!?! If FACT was just to capture 10% of the market share, which is possibly silly when you consider how far superior their technology in comparison to their competition, that’s $6B! So, if they capture 10% of a 40,000,000 transactions would equal 4,000,000 transactions! What could the revenue look like for (OTC-FCTI) if they were able to capture 10%? Here is a local “art expert” that reviews the piece with his/her naked eye and charges $150, with no technology! LINK 4,000,000 authenticating transactions X $150 = $600,000,000! Annually Their competition is a local “art expert” who evaluates the art with their naked eye and then authenticates the art with a piece of paper called a COA. That is it! Imagine if there was a machine that uses a computer algorithm to verify authenticity down to a size smaller than a grain of sand?!?! Well there is and we are excited. Is that worth $150, $300 or $600?!?! Will they penetrate 10%, 15% or 20% of the market? Let’s be honest, even in the worst case scenario, that is $600 Million US Dollars annually!

2. FACT has developed/redesignated a technology that is truly pioneering in the art authentication industry.

F.A.C.T, (OTC: FCTI), Secured Device is the ONLY PORTABLE SOLUTION ON THE MARKET that uses technology to create a “Digital Fingerprints” from the Physical Artwork for Verification and Condition Reporting. They have adapted the same forensic ballistics technology used by global law enforcement agencies to the art world! An “interferometer’ – a high tech machine – captures a scan of the painting down to 1/50th the size of a human hair. Right down to the pressure on an artist’s brush stroke! Current scans are compared to previous scans by a high tech computer generated algorithm to make sure that it is the same painting! This creates a Tangible Links between the Owner, Artwork and Database Record through Identification of a “Digital Fingerprint” from the Scans. LINK (Investor Deck on the website). I apologize for typing in caps above but that is an especially important concept that the average investor needs to play close attention. The current industry standard is “art experts” certifying with their naked eye that it’s the original, with their naked eye, with the possibility of Millions of dollars on the line. This archaic method lends itself to fraud because technology has outpaced the human eye. The art fraud market is estimated by the FBI to be a $6B industry! In fact, an expert in the field, 9Mousai founder, Richard Hammond, offers some advice: “A certificate of authenticity is essential when buying and selling art to prove legitimacy,” he reveals. “The certificate must be signed by the artists or a representative or it isn’t worth the paper it’s printed on, and there are fakes around, so beware.” LINK Let me repeat, there are fakes around, not anymore. FACT will literally revolutionize the art authenticating landscape forever. Investors are you excited? Everyone is excited for this IPO, except for art criminals, they are petrified!

3. Its groundbreaking technology is positioned in a $6B industry with no market leaders!

What other $10B+ industry has no clear-cut industry titan that dominates it, none that I can think of. This technology will become the gold standard of the art verification world and that world is worth $6B! No other verification system uses technology and the actual painting! For comparison purposes, the online dating industry is a $3 billion dollar a year industry! LINK Let’s take a minute to digest that research. In the example above, if FACT can capture 15% of the market at a $600 service fee, they will produce revenue in excess of $3 BILLION! However, there is no Ok Cupid in the space! No Bumble! No Tinder! Just a vacuum of opportunity with no competitors! A bunch of Ma and Pa stores before the advent of Walmart.

4. It’s an IPO with groundbreaking technology in a $6B industry with no market leader. Yes I repeated myself, because you should pay attention!

It’s an IPO, ground floor opportunity in a brand-new technology in a multibillion-dollar industry. I could do the easy lay up here and compare it to all the crazy IPOS which had 300%, 800%, and 1,200% gains but that is just too easy! As savvy investors we have heard all those war stories and for me that would feel like I lost a little bit of my soul by going somewhere so transparent. So, I will keep this point short and sweet and remind you for a third time, it’s an IPO with groundbreaking technology in a $6B industry with no market leader!

5. Do I have your attention now? If I don’t, I will when you find out that they have multiple ways to monetize the hardware and software!

FINANCIAL INSTITUTIONS Art-secured lenders who accept art as loan collateral can verify whether that art is an original or a forgery. If a bank is loaning a couple of hundreds of thousands of dollars I’m sure that institution will have no problem paying for authentication to protect their investment. Last year over $24B in loans were secured by art! Or, even better yet, they make it mandatory, kind of like a Car FAX is mandatory today for used car purchases! AUCTION HOUSES Companies like Christie’s and Sotheby’s can verify the legitimacy of a piece before putting it up for sale. The top auction houses had over $24.2B in sales last year! Once one of the big auction houses makes it mandatory, every other auction house will probably follow suit! MUSEUMS & GALLERIES Art organizations can collect data to manage their portfolio and verify the legitimacy of their collections. Galleries had over $38.6B in sales last year! I would imagine that insurance companies will make this technology standard operating procedures before they will even insure a museum or gallery. ART INSURERS Fraud prevention departments can ensure the legitimacy of insured works to decrease unlawful payouts. Insurance is anywhere from 1% to 7% of the value of the painting. Again, similar to auction houses, once one major insurance provider makes it mandatory, the whole market will probably follow. ART TRANSPORTATION & STORAGE Companies can ensure transferred assets are legitimate and prove lack of quality loss upon delivery. Over 14MM pieces of art are moved annually! FACT also offers RFID chips to monitor the art as it is displayed or in transit! GPS tracking and block chain technology has arrived in the industry that started millennia ago in Europe. INDIVIDUAL COLLECTORS Art enthusiasts scan originals before lending them to museums and galleries to ensure they get the original back later. They can also track and manage their collections securely stored on blockchain! The best way to possibly protect your investment for generations to come, to authenticate the valuable art with the most sophisticated technology in the industry

6. FACT would just be a Tech Company if it wasn’t for these incredible assets, now they are a force to be reckoned with in the art verification industry!

The executive team is impressive! Patricia Trompeter, CFO & COO, brags pedigree hailing from the monster GE Capital! Ardavan brings an extremely critical component to the executive team, art industry expertise! He has decades of experience in the Forensic Art Certification industry. Michael Arbach, CIO, has written code that has Billion of dollars of transaction in the securities market, as in, trading stocks! Can I it gets any better? Yes, Jeff Felske, Co-Founder was an executive at Disney, if I had a microphone, I would drop it!

Patricia TrompeterCFO & COO Patricia spent 15+ years in the financial services industry with GE Capital. She held several positions in various divisions including CFO, Controller, Operations Leader, and M&A. After a short break to focus on philanthropic opportunities and family, Patricia founded Webbs Hill Partners. She holds a B.Sc. in Finance/Economics and Management Information Systems from Marquette University. Ardavan TajbakhshCo-Founder & CTO Ardavan holds a B.Sc. in Mathematics & Computer Science from Canada’s Capital University, where he was hired as a Senior Programmer Analyst after graduation. When he ended his career there, he was the Enterprise Architect for the University’s Enterprise Technology Infrastructure. He left this position to become the Solution Architect for ALIAS, before becoming the Vice- President and Chief Technology Officer at Pyramidal Technologies Ltd. He brings his decades of experience to the Forensic Art Certification Technology team. Jeff FelskeCo-Founder Jeff started his career as the national sales manager at Disney Canada. After developing his skills, he became the V.P. of sales for Lyons Group and In 1995, Jeff transitioned again becoming a V.P. and partner of GTS acquisitions. It was here that Jeff applied his unique skills and entrepreneurial passion, to open Target Marketing Group. He exclusively represented many A-list video game developers. Jeff then shifted his focus to funding and guiding the creation of ALIAS, which he now brings to F.A.C.T. Michael ArbachCIO Michael is a business-oriented software engineer with a proven 17 year track record building high performance solutions for top tier companies using emerging technologies. Code produced by Michael has processed billions of dollars in securities transactions. Today some of the largest banks and organizations in the U.S. rely on his software to power millions of users across various applications. He is an early blockchain enthusiast, developer, and investor. Michael holds degrees in Applied Mathematics and Computer Science. He is fluent in four languages and enjoys flying small airplanes. As a quick recap, these are the 6 reasons you want to place (OTC-FCTI) on your watchlist today!

  1. Numbers do not lie, 40 million art transactions in 2018!
  2. A.C.T Secured Device is the ONLY PORTABLE SOLUTION ON THE MARKET UTILIZING “Digital Fingerprints” oh and it is a $6B a year industry!
  3. What other $10B+ industry has no clear-cut industry titan that dominates it, not online dating apps which is a $3B a year industry. This technology will become the Gold Standard of the art verification world!
  4. It is an IPO, enough said!
  5. There are 6 ways to monetize this technology, I do not even think dating apps have that many revenue streams!
  6. The Executive team boasts GE Capital, Disney, and billions of transactions in the securities market!

Happy Trading, laptop drop!

Disclaimer :Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).We publish the Information on our website, smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Owner of JBN partners purchased Shares of FCTI in September on the open market and does plan to sell those shares within the next 90 days. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, FACT, Inc. Small Cap Exclusive has been hired by FACT, Inc. for a period beginning on November 13, 2020 to publicly disseminate information about (TNCP) via website and email. We have been compensated $22,000. We will update any changes to our compensation.

Read full disclaimer here.

read more
Collection Sites Launches Business to Business Sales Initiatives – Provides Update With February Sales of 30,717 Tests at an Average Price of $98 per Test

Collection Sites Launches Business to Business Sales Initiatives – Provides Update With February Sales of 30,717 Tests at an Average Price of $98 per Test

Read original article here.

Collection Sites launched multi-week custom testing solutions for a high-school athletics department in Redlands, California and a film production company in Los Angeles as part of its new business-focused sales strategy. Further, Medivolve announces an investor webinar Tuesday, March 23rd at 1 pm ET

TORONTO, March 18, 2021 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to provide investors with a sales update and announces the launch of a new business to business sales strategy, including the initiative of two custom testing solutions.

On Monday, March 8th, 2021, Collection Sites launched two multi-week custom COVID-19 testing programs as part of its new business-focused testing services. Moving forward, Collection Sites will be dedicating additional efforts to securing testing contracts with businesses across the United States to provide custom testing solutions.

The first program is with a TV & Film production studio based in Los Angeles, where Collection Sites staff provide 24 hour PCR test results on-site for crew, talent and staff in accordance with the required COVID-19 testing policies. The testing program will last four weeks, with approximately 500 PCR tests expected to be completed.

The second program is with the athletics department of a school district in Redlands, California. Collection Sites will supply and conduct on-site rapid antigen tests on students, athletes, and staff as required by the athletics department. The testing program will last until the end of June 2021, where up to 3,750 rapid antigen tests can be completed over the period.

February Sales

During the month of January, the Company realized the sale of 30,717 tests at an average sale price of $98 per test across its network. Approximately 59% of the sales were cash pay, with the balance as insurance sales. The Company continued to see the strongest demand for antigen tests, followed by antibody and then PCR.

“In February we saw another solid month of sales with over 30,000 tests conducted across our network. While we experienced some operating challenges due to winter weather, particularly in Texas and along the east coast during the month, we are still very happy with the sales results,” commented Medivolve CEO Doug Sommerville. “As vaccination efforts rollout, we anticipate retail demand to soften and as such are turning to exciting new sales initiatives focused on custom testing solutions for businesses. While COVID cases have receded across America, we believe the need for proper testing will remain for the foreseeable future. This also highlights the strategic importance of our telehealth initiatives and the launch of a disruptive and sustainable business model that helps to provide accessible and convenient medical services to our patients.”

Upcoming Corporate Webinar

Medivolve is pleased to announce it is hosting a Corporate Update webinar, on Tuesday, March 23rd at 1 pm ET that will provide investors with an update on the Company’s recent business developments.

Registration Link: https://us02web.zoom.us/webinar/register/WN_tmyDKJWYQTGoviFFM1zq7Q

Specifically, the webinar will feature Medivolve CEO Doug Sommerville and Dr. Glenn Copeland to elaborate on Collection Sites’ telehealth strategy. Dr. Glenn Copeland is a medical advisor to Medivolve and CEO of Glenco Medical, a Medivolve partner company. With Dr. Copeland’s guidance, Medivolve and Collection Sites are developing telehealth plans that include remote patient monitoring and virtual care, among other offerings. Collection Sites intends on leveraging its network of sites and large customer database to market these new services and launch a series of mobile clinics.

About the Collection Sites

The pop-up labs will be managed by Las Vegas based company Collection Sites, LLC and powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. Appointments and payments will be handled through an online portal www.testbeforeyougo.com.

The key to flattening the curve is to increase testing.

The testing centers will offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

For more information about the pop-up lab, the available sites and services visit www.testbeforeyougo.com.

About Medivolve Inc.

Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:4NC) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas: prevention, detection, and treatment.

Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

Medivolve’s primary focus is to provide convenient and assessable medical services for testing of the COVID-19 virus to help combat the pandemic. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments to be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

For additional information, please contact:

Doug Sommerville, [email protected]

For investing inquiries please contact:[email protected]

For US media enquires please contact:Veronica [email protected]

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to sales results; the proposed roll-out of business testing; the Company’s expansion into telehealth; projected timelines for testing results; projected revenues from the testing; the pursuit by Medivolve of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

read more
Medivolve Signs Agreement to Acquire 100% of Modern Rx LCC, a Las Vegas based Pharmacy

Medivolve Signs Agreement to Acquire 100% of Modern Rx LCC, a Las Vegas based Pharmacy

Read original article here.

As part of its telehealth strategy, Medivolve has acquired a pharmacy to better serve Collection Sites telehealth patients as the program launches. Further, Medivolve will host an investor webinar Tuesday, March 23rd at 1 pm ET

TORONTO, March 16, 2021 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to announce the signing of a binding Letter of Intent (LOI) to acquire a 100% equity interest in Modern Rx LLC, a Las Vegas based pharmacy from shareholders of Modern. This pharmacy is expected to serve as an important component of Medivolve’s telehealth strategy, where Collection Sites telehealth patients will be able to have their presecription filled directly through the pharmacy’s operating license.

“As Medivolve developed its telehealth strategy, we saw the need for the ability to fill patients prescriptions directly. As such, management sought out an operating pharmacy that would imemdiatley allow Collection Sites to offer valuable telehealth services to patients when the program launches,” commented Medivolve CEO Doug Sommerville. “The Modern Rx company provides Medivolve with the necessary licensing and infrastructure at a price that is accretive for shareholders. As Medivolve’s telehealth program launches, we anticipate the additional services offered through Modern Rx, and its network of pharmacy relationships nationally, will be an integral component of the telehealth solution.”

About the Transaction

Medivolve will acquire a 100% equity interest in Modern from the shareholders of the company. As consideration for the acquisition of a 100% equity interest in Modern, Medivolve shall pay to the Modern shareholders: (i) cash consideration of US$100,000; and (ii) one (1) million common shares of Medivolve. The completion of the transaction to acquire 100% of Modern Rx LLC is subject to customary closing conditions, including due diligence to the satisfaction of Medivolve, the parties entering a definitive agreement and NEO Stock Exchange approval. No finder fees are payable in connection with, and no change of control of Medivolve will result from, the transaction.

Upcoming Corporate Webinar

Medivolve is pleased to announce it is hosting a Corporate Update webinar, on Tuesday, March 23rd at 1 pm ET that will provide investors with an update on the Company’s recent business developments.

Registration Link: https://us02web.zoom.us/webinar/register/WN_tmyDKJWYQTGoviFFM1zq7Q

Specifically, the webinar will feature Medivolve CEO Doug Sommerville and Dr. Glenn Copeland to elaborate on Collection Sites telehealth strategy. Dr. Glenn Copeland is a medical advisor to Medivolve and CEO of Glenco Medical, a Medivolve partner company. With Dr. Copeland’s guidance, Medivolve and Collection Sites are developing telehealth plans that include remote patient monitoring and virtual care, among other offerings. Collection Sites intends on leveraging its network of sites and large customer database to market these new services and launch a series of mobile clinics.

About the Collection Sites

The pop-up labs will be managed by Las Vegas based company Collection Sites, LLC and powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. Appointments and payments will be handled through an online portal www.testbeforeyougo.com.

The key to flattening the curve is to increase testing.

The testing centers will offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

For more information about the pop-up lab, the available sites and services visit www.testbeforeyougo.com.

About Medivolve Inc.

Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:4NC) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.

Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

Medivolve’s primary focus is to provide convenient and assessable medical services for testing of the COVID-19 virus to help combat the pandemic. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

For additional information, please contact:

Doug Sommerville, CEO [email protected]

For investing inquiries please contact: [email protected]

For US media enquires please contact: Veronica Welch [email protected]

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the expansion of COVID-19 testing sites; the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by Medivolve of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

read more
Medivolve Inc. (OTC-COPRF, NEO-MEDV) is Possibly Ready for a Big Move

Medivolve Inc. (OTC-COPRF, NEO-MEDV) is Possibly Ready for a Big Move

Medivolve Inc. (OTC-COPRF, NEO-MEDV) is possibly ready for a big move, traders place this on your watchlist immediately!

 Here are SIX reasons why Medivolve is just warming up!

  1. The chart is potentially very promising.
  2. The Testing Network is established and nation-wide.
  3. Covid is here to stay!
  4. Recent press releases are incredible!
  5. Medivolve (COPRF/MEDV) is poised to be a major disrupter of medical services due to their low CPA (Cost Per Acquisition).
  6. A leader is a dealer in hope and the leadership team embodies hope for traders!

Medivolve

Company Name: Medivolve, Inc.

Ticker: (OTC-COPRF, NEO-MEDV)

52 Week High: $.67

Current Trading Price: $.32

Market Trend: Bullish

Company Summary:  Medivolve, Inc. has a substantial collection of leased sites for COVID-19 testing, offering convenient access to rapid antibody and antigen tests; these tests take 8-10 minutes to administer, provide results in less than 24 hours and cost under $100 along with standard PCR tests. The company is expanding into tele-health and tele-diagnostics which they intend to capture a significant market share through their impressive CPA model for obtaining new clients, where they can disrupt the medical service industry with hundreds of convenient walk up locations rather than the traditional come and wait in a Covid-19 saturated doctors lobby for your hour late appointment. 

The chart is potentially very promising!

February 04, 2021 

In order to maximize operational efficiency, Collection Sites is conducting a state by state expansion where possible. The new sites are currently located on the properties of Simon’s Property Group, an investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations and an S&P 100 company as well as Sandor Development Group. Additional sites are expected to be open in Texas, Florida, and Georgia within the coming weeks.

November 11th – Collection Sites Announces Agreement to Offer COVID-19 Testing Services and Protocols for The Elf On The Shelf’s Magical Holiday Journey

November 17th – QuestCap Announces Planned Name Change to Medivolve Along With Transition to Single Purpose Medical Company

December 1 – Collection Sites Expands Convenient COVID-19 Testing Across America with 25 Additional Testing Sites

January 5th 2021 – Medivolve (COPRF/MEDV) announces a C$5M bought deal private placement led by Canaccord Genuity.

Medivolve entered into an agreement with Canaccord Genuity Corp., on behalf of a syndicate of underwriters (collectively the “Underwriters”), pursuant to which the Underwriters have agreed to purchase on a bought deal private placement basis, 20,000,000 units of the Company (“Units”) at a price of C$0.25 per Unit (the “Issue Price”), for aggregate gross proceeds of C$5,000,000

The press releases over the last three months have garnered serious attention by Wall Street, take a look at this CHART.

Medivolve Chart 1

The chart above is potentially very promising with some serious consolidation taking place over the last month. Out of the first 34 volume bars on this chart 24 are green, closing positive for the day, which represents 71% positive days. Hence, the stock reacted with an ascending, bullish, chart line. 

The run started on 11/27/2020 at a price per share of $.125 and due to those “buying” days it reached a high of $.60 on 1/20/21 which represents a 380% gain over the specified period. 

Now let’s look at the consolidation that took place after the amazing run of 380% gains, there were 22 volume bars after the run to $.60 with 13 representing a sell off day, 60%, hence the traders who were happy with their gains from the run exited their positions. This is consolidation, which creates a prime environment for another massive possible price increase due to the lack of sellers creating downward pressure. 

In short, many people bought the COPRF/MEDV on the two month run to $.50-$.60 then sellers started to exit their positions creating downward pressure resulting in the share price falling from the high of $.60 down to $.33. Moreover, $.33 still represents a 164% gain from the November price of $.125 which reveals this stock could be primed for another move holding a much higher main trend line than November!

This channel is poised for a possible major breakout!

Medivolve Chart 2

Let’s review the 5 day chart and one can see the channel-line, top line, and the main trend, bottom line, is a perfect set up for a possible strong run. What does that mean? A bullish channel traditionally signals technical traders to watch or buy a stock based on the ascending main trend line and the corresponding channel-line. 

The Testing Network is established and nation-wide!

Medivolve has signed with a major multi-billion dollar premium mall operator to set up these  Collection Sites COVID-19 testing centers to offer convenient access to rapid antibody and antigen tests – which take 8-10 minutes to administer and provide results in less than 24 hours. The sites also offer regular RT-PCR. The testing centres are powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. 

All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

Medivolve (COPRF/MEDV) issues Huge News in regards to strategic partners, who will be next?

Medivolve Chart 3

Covid is here to stay!

Feb 3rd, just a few weeks ago, had the third largest amount of cases of Covid-19 in the United States.

Think about this, they made $7.1M in just January and that was just a few months of the company being in business! What will Q2 look like?

During the month of January, the Company realized the sale of 73,973 COVID-19 tests at an average sale price of $96 per test across it’s expanding network. Approximately 52% of the sales were cash pay, with the balance as insurance sales. The Company continued to see the strongest demand for antigen tests, followed by antibody and then PCR.

So, the question is, how long will Covid testing be a viable source of income?

The answer: Covid is unfortunately here to stay!

Let’s look at the latest numbers:  Are we going up? Are we holding the average? Or going down?

Almost 71,000 new cases of COVID-19 were reported in the United States on February 22, 2021. 

If those numbers hold true, there will be 2,130,000 new cases (71,000 X 30 days) that have to be tested to be confirmed. Let’s look at the last 13 months to see if the Feb 22 numbers are going up, holding the average or going down.

Between January 20, 2020 and February 22, 2021 there have been almost 28 million confirmed cases of COVID-19 which means that the monthly average is 2,153,000 (28 million / 13 months)  which is almost exactly at the projected average derived from the Feb 22 numbers, which means we are 100% still in the grips of this deadly virus.

Recent press releases are incredible!

February 4, 2021

Sales of 73,973 Tests at $96 , that is over $7M in just January!

During the month of January, the Company realized the sale of 73,973 COVID-19 tests at an average sale price of $96 per test across it’s expanding network. Approximately 52% of the sales were cash pay, with the balance as insurance sales. The Company continued to see the strongest demand for antigen tests, followed by antibody and then PCR.

“We are thrilled by the strong sales performance in the month of January and are excited for future sales with the rapid growth of our network,” commented Collection Sites.

As we already examined above, the Covid numbers are holding to the 13 month average, so the $7.1M in revenue for Medivolve should be a solid projection for the near future. Possibly, as Americans grow tired of masks, quarantines and become lackadaisical in conjunction with warmer weather, get-togethers both public and private, we believe the covid cases will be on the rise as well.

February 18, 2021 

Medivolve Announces Launch of Investor Awareness Campaign

As a trader, I absolutely love seeing emerging companies paying for awareness campaigns. If a company believes in it’s product/service and is willing to have skin in the marketing game, well, it is a very good sign. Medivolve has contracted with three of the most respected investor relations firms in the country:  EMC Marketing Services, Winning Media Marketing Services & Amherst Baer Marketing Services. 

These three firms are savants when it comes to creating awareness around some of the biggest investments in the last decade. Let’s get ready fellow investors, this could be a legendary ride! One of those war stories you tell on your front porch, all eyes on you, hanging on every word as you hear exclaimed, “get out of here, no way!” Let’s take a good look at the companies and monies spent over the duration.

EMC Marketing Services

Medivolve entered into an agreement for electronic media and webcast services, design, development and dissemination services with Emerging Markets Consulting LLC (EMC), with respect to EMC providing investor relation services to the company. Effective February 24, 2021, the EMC agreement has an initial term of 90 days, wherein the company will pay EMC a non-refundable fee of US$250,000.

Winning Media Marketing Services

Medivolve entered into an agreement for strategic digital media services, marketing and data analytics services with Winning Media LLC (WM). Effective February 8, 2021, the WM agreement has an initial term of 90 days, wherein the company will pay WM a non-refundable fee of $250,000. 

Amherst Baer Marketing Services

Medivolve has retained Amherst Baer Consultancy Corp. (ABCC) of Langley, B.C., as investor relations consultant to prepare a marketing campaign for the company. ABCC will be paid $70,000 a month for a three-month contract.

Medivolve (COPRF/MEDV) is poised to be a major disrupter of medical services due to their low CPA of customers

Let’s take a look at the Tele-Health & Tele-Diagnostic Industry

In a press release dated February 22nd, 2021 Medivolve has “A large network of Collection Sites and intends on leveraging its network and large customer database to market these new services and launch a series of mobile clinics.”

What is Tele-Health?

The Health Resources Services Administration defines telehealth as the use of electronic information and telecommunications technologies to support long-distance clinical health care, patient and professional health-related education, public health and health administration. Technologies include videoconferencing, the internet, store-and-forward imaging, streaming media, and terrestrial and wireless communications. Link

What is the Tele-Health market size?

The telehealth market growth will increase by $95.72 billion during 2019-2024. Link 

Why should Medivolve enter into this vertical?

First and foremost, they are mitigating the risk if Covid-19 is eradicated then they will have an established vertical to monetize with their current customer base. The announcement by Medivolve to enter into the TeleHealth sector makes a lot of sense due to their existing customer base, strategic partnerships and to develop an exit strategy when Covid numbers go down. Well done, well done!

CPA, not the accountant, Cost Per Acquisition, it’s the name of the game!

I remember an interview with ClickFunnels’ Russel Brunson and I will never forget it; he said, the name of the game is being able to pay a higher price for a client than your competition. So, if you can create a higher AOV (Average Order Value) then, you can pay more to acquire the client. If you are scaling and penetrating the market enough you can actually start eliminating weak competitors by cutting off their ability to acquire clients by increasing the CPA. It’s reminiscent of Genghis Khan’s legendary military tactic of disrupting the food supply and starving out your enemies. I’m not alluding to Medivolve engaging in such practices but with their massive customer database already acquired to repurpose that database to create new revenue streams would create a massive competitive advantage!

They don’t have to go pay per clicks, hire an agency or pay for a team of sales reps to ring doorbells, they already have a list of thousands of clients who prefer to conveniently walk up to a testing facility on their way to Target. I imagine the client after 8 minute experience said, I sure wish all medical experiences were like this! They will tap into this customer list and it should be even bigger than their current operations!

“A leader is a dealer in hope.” —Napoleon Bonaparte

You’re only as good as your people, let’s take a look. 

Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space.  This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

Doug Sommerville is a veteran leader in the North American medical, pharmaceutical and technology industries. Prior to joining Medivolve, Mr. Sommerville held the role of Head of Country for Canada for Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd. (“Teva”), the world’s leading provider of generic medicines. In this role, Mr. Sommerville was responsible for Teva’s third largest global subsidiary, with sales in excess of $1.3 billion. Douglas led all aspects of the company’s commercial, distribution, demand planning and customer operations – aligning and coordinating all company functions, production, supply chain, regulatory and global support functions. Douglas was also the Chairman of the Canadian Generic Pharmaceutical Association up until his retirement from Teva Canada in 2018.

Previous to his tenure at Teva Canada, Mr. Sommerville was Global Vice President, Infusion Systems with Baxter Healthcare International (“Baxter”), one of the world’s largest medical, pharmaceutical and technology companies. In his role, Douglas was responsible for the company’s infusion pumping devices and intravenous administration sets worldwide, as well as pain management and ambulatory infusion devices, working with Baxter’s product development, regional sales and marketing teams globally.

Lawrence Steinman, MD  is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on antigen specific tolerance in autoimmune disease and in gene therapy for degenerative neurologic diseases. He has elucidated what provokes relapses and remissions in multiple sclerosis (MS). He is taking forward a pivotal clinical trial with antigen specific tolerization therapy for type 1 diabetes. He serves as attending neurologist at Stanford’s Lucille Packard Children’s Hospital.

Steinman was senior author on the 1992 Nature article that led to the drug Tysabri, approved for MS and Crohn’s disease. Tysabri has been taken by over 200,000 individuals with MS.

Dr. Glenn Copeland possesses over 45 years of experience in both orthopaedic treatment and sports medicine, Dr. Glenn Copeland is one of North America’s most prominent foot and ankle specialists.

He has established unique and authoritative treatments specializing in both surgical and non-surgical procedures of the foot and ankle.

Dr. Copeland has founded and directed several highly successful medical companies including Footmaxx Inc., which converted orthopaedic evaluation of the lower extremity from moulding technology to pressure and motion mapping. Dr. Copeland was successful in opening over 1,880 clinics globally.

Between 2002 and 2008, Dr. Copeland was selected to be the founder, chairman, and CEO of Cleveland Clinic Canada. Cleveland Clinic is universally regarded as one of the top three medical institutions in the world.

He was recruited in 2008 by Mount Sinai Hospital in Toronto to establish the Rehab and Wellbeing Centre and Sports Medicine Centre, which continues to thrive, seeing over 10,000 patient visits each year.

These are 5 very good reasons why Medivolve should be on your watchlist. 

  1. The Testing Network is established active and nation-wide massive and growing with hundreds of additional sites.
  2. Covid is here to stay!
  3. Recent press releases are incredible!
  4. Medivolve (COPRF/MEDV) is poised to be a major disruptor of medical services due to their low CPA (Cost Per Acquisition)
  5. A leader is a dealer in hope and the leadership team embodies hope for us traders!

Happy Trading and remember my adage, “Never try to catch a falling knife!”

Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, Medivolve, Inc. Small Cap Exclusive has been hired by Medivolve, Inc. for a period beginning on March 3, 2021 to publicly disseminate information about (COPRF) via website and email. We have been compensated $50,000 USD. We will update any changes to our compensation.

Read full disclaimer here.

read more